About: The role of the urologist, BCG vaccine administration, and SARS‐CoV‐2: An overview

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The role of the urologist, BCG vaccine administration, and SARS‐CoV‐2: An overview Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The role of the urologist, BCG vaccine administration, and SARS‐CoV‐2: An overview
Source	Medline; PMC
abstract	OBJECTIVES: To summarize the available literature regarding bacillus Calmette‐Guerin (BCG) administration, severe acute respiratory syndrome conoravirus‐2 (SARS‐CoV‐2), and the resulting clinical condition coronavirus disease (COVID‐19) in light of recent epidemiologic work suggesting decreased infection severity in BCG immunized populations while highlighting the potential role of the urologist in clinical trials and ongoing research efforts. MATERIALS AND METHODS: We reviewed the available literature regarding COVID‐19 and BCG vaccination. Specifically, the epidemiologic evidence for decreased COVID‐19 morbidity in countries with BCG vaccination programs, current clinical trials for BCG vaccination to protect against COVID‐19, potential mechanisms and rationale for this protection, and the role of the urologist and urology clinic in providing support and/or leading ongoing efforts. RESULTS: Epidemiologic evidence suggests that the crude case fatality rates are lower for countries with BCG vaccination compared to those without such programs. Four prospective, randomized clinical trials for BCG vaccination were identified including NCT04348370 (BADAS), NCT04327206 (BRACE), NCT04328441 (BCG‐CORONA), and NCT04350931. BCG administration may contribute to innate and adaptive immune priming with several opportunities for translational research. CONCLUSIONS: The urologist’s expertise with BCG and the infrastructure of urologic clinics may afford several opportunities for collaboration and leadership to evaluate and understand the potential role of BCG in the current COVID‐19 pandemic.
has issue date	2020-06-22(xsd:dateTime)
bibo:doi	10.1002/bco2.21
bibo:pmid	32835353
has license	cc-by
sha1sum (hex)	b2d4f03eb4c96e2385bdf220a16b0568206ee9e8
schema:url	https://doi.org/10.1002/bco2.21
resource representing a document's title	The role of the urologist, BCG vaccine administration, and SARS‐CoV‐2: An overview
has PubMed Central identifier	PMC7361196
has PubMed identifier	32835353
schema:publication	BJUI Compass
resource representing a document's body	covid:b2d4f03eb4c96e2385bdf220a16b0568206ee9e8#body_text
is schema:about of	named entity 'World Health Organization' named entity 'intravesical' named entity 'bladder' named entity 'BCG' named entity 'BCG' named entity 'lungs' named entity 'IL1Ra' named entity 'cytokine storm' named entity 'urologists' named entity 'BCG vaccination' named entity 'yellow fever' named entity 'bladder cancer' named entity 'BCG' named entity 'intravesical' named entity 'human disease' named entity 'bladder cancer' named entity 'immune responses' named entity 'Infection' named entity 'bladder cancer' named entity 'immunomodulatory' named entity 'sound studies' named entity 'World Health Organization' named entity 'infection' named entity 'BCG' named entity 'nursing home' named entity 'antigens' named entity 'TH2' named entity 'SARS-CoV-1' named entity 'BCG vaccination program' named entity 'live, attenuated' named entity 'socioeconomic status' named entity 'animal models' named entity 'clinical trials' named entity 'BCG' named entity 'respiratory infections' named entity 'vaccination program' named entity 'placebo' named entity 'SARS-Cov-2' named entity 'infection' named entity 'yellow fever' named entity 'urologist' named entity 'urologists' named entity 'animal models' named entity 'urologist' named entity 're-purpose' named entity 'Dutch' named entity 'SARS-Cov-2' named entity 'inoculate' named entity 'respiratory tract' named entity 'yellow fever virus' named entity 'bladder cancer' named entity 'Urologic' named entity 'BCG' named entity 'vaccination' named entity 'BCG vaccination' named entity 'BCG vaccination' named entity 'BCG vaccination' named entity 'lung' named entity 'BCG' named entity 'BCG' named entity 'BCG' named entity 'influenza' named entity 'randomized controlled study' named entity 'BCG' named entity 'BCG' named entity 'BCG vaccination' named entity 'mucosal' named entity 'bladder cancer' named entity 'tuberculosis' named entity 'Viral replication' named entity 'BCG vaccination' named entity 'yellow fever' named entity 'tumors' named entity 'healthcare systems' named entity 'IFNa' named entity 'TH1' named entity 'vaccination' named entity 'bacteria' named entity 'intravesical' named entity 'virus' named entity 'developing nations' named entity 'BCG vaccine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software